BP asociado a inhibidores puntuales del sistema inmune...
Diagnostic and Therapeutic Differences Between Immune Checkpoint Inhibitor–Induced and Idiopathic Bullous Pemphigoid
Abstract
Bullous pemphigoid (BP) is a serious, rare complication from immune checkpoint inhibitors (ICIs). While most dermatologic immune-related adverse events (irAEs) present early and are mild, ICI-induced BP (ICI-BP) manifests months into therapy and can prompt ICI discontinuation and severe immunosuppression. Following irAE management guidelines, providers rely on systemic corticosteroids - which, at high doses, may confer poorer oncologic outcomes for ICI patients. Our study aims to identify diagnostic and therapeutic differences between ICI-BP and idiopathic BP (iBP) to assist providers in prompt recognition and management of this skin toxicity.
The British Journal of Dermatology
Diagnostic and Therapeutic Differences Between Immune Checkpoint Inhibitor-Induced and Idiopathic Bullous Pemphigoid: A Cross-Sectional Study
Br J Dermatol 2020 Jun 12;[EPub Ahead of Print], GE Molina, KL Reynolds, ST ChenSent from my iPhone
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Skin Care Physicians of Costa Rica
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home